The total number of records retrieved from this search are 11. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_2809	Virus nameAdenovirus	Virus strainG47-delta	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus strain in combination with palcitaxel (4 nm)	Immune gene insertion in viral genomeNo	Source of cell lineSun-sen university cancer centre, china	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-468	Concentration of cell line2000 cells per well	In-vitro toxicityNA	AssayCell counting kit-8	In-vitro virus concentration1 MOI	In-vitro result20% cells viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedMitotic arrest and induction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID23525624
IDOV_2810	Virus nameAdenovirus	Virus strainG47-delta	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus strain in combination with palcitaxel (8 nm)	Immune gene insertion in viral genomeNo	Source of cell lineSun-sen university cancer centre, china	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-468	Concentration of cell line2000 cells per well	In-vitro toxicityNA	AssayCell counting kit-8	In-vitro virus concentration2 MOI	In-vitro result18% cells are viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedMitotic arrest and induction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID23525624
IDOV_2811	Virus nameAdenovirus	Virus strainG47-delta	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus strain in combination with palcitaxel (16 nm)	Immune gene insertion in viral genomeNo	Source of cell lineSun-sen university cancer centre, china	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-468	Concentration of cell line2000 cells per well	In-vitro toxicityNA	AssayCell counting kit-8	In-vitro virus concentration4 MOI	In-vitro result10% cells are viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedMitotic arrest and induction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID23525624
IDOV_2812	Virus nameAdenovirus	Virus strainG47-delta	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus strain in combination with palcitaxel (16 nm)	Immune gene insertion in viral genomeNo	Source of cell lineSun-sen university cancer centre, china	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-468	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for MDA-MB-468 (5.0E+6 cells)	In-vivo virus concentration2.0E+5 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor volume after 35 days	Mode of deliveryIntratumoral	Pathway inducedMitotic arrest and induction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID23525624
IDOV_4292	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast carcinoma	Cell lineMDA-MB-468	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 pfu	In-vitro result43.7 % cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis	Immunogenic effectNA	Clinical trialNA	PMID26373347
IDOV_5554	Virus nameReovirus	Virus strainReovirus serotype 3	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-468	Concentration of cell line60% confluency	In-vitro toxicityNA	AssayNA	In-vitro virus concentration40 MOI	In-vitro resultCell viability drops to 12.7% after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectNA	Clinical trialNA	PMIDUS6994858
IDOV_5555	Virus nameReovirus	Virus strainReovirus serotype 3	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-468	Concentration of cell line60% confluency	In-vitro toxicityNA	AssayNA	In-vitro virus concentration40 MOI	In-vitro resultCell viability drops to 8.8% after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectNA	Clinical trialNA	PMIDUS6994858
IDOV_5556	Virus nameReovirus	Virus strainReovirus serotype 3	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-468	Concentration of cell line60% confluency	In-vitro toxicityNA	AssayNA	In-vitro virus concentration40 MOI	In-vitro resultCell viability drops to 3.6% after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectNA	Clinical trialNA	PMIDUS6994858
IDOV_5588	Virus nameReovirus	Virus strainReovirus strain T3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman breast carcinoma cell line	Cell lineMDA-MB-468	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismSCID mice xenograft for MDA-MB468 (1.0E+5)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to 38.33gm compared to control 128.54 after 4 weeks	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS7374752
IDOV_5606	Virus nameNewcastle disease virus	Virus strainNDV-MK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman breast carcinoma cell line	Cell lineMDA-MB-468	Concentration of cell line80% confluency	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration44 pfu	In-vitro result50% of cancer cell death occurs	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectInduction of IFN-Gamma production	Clinical trialNA	PMIDUS7470426
IDOV_5825	Virus nameNewcastle disease virus	Virus strainNDV-PPMK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman breast carcinoma cell line	Cell lineMDA-MB-468	Concentration of cell line80% confluency	In-vitro toxicityNA	AssayNA	In-vitro virus concentration44 pfu	In-vitro result50% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS8105578